CClinicalTrials.gg
CompletedNCT03082040Updated Jun 5, 2020

A Home-based Breathing Training on Menopausal Symptoms

An interventional study of home-based breathing training in Menopause and Menopause Related Conditions, sponsored by Ministry of Science and Technology, Taiwan. Completed at 1 site in Taiwan. Open to female participants aged 45 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-05.

Sponsored by Ministry of Science and Technology, Taiwan · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
45 Years to 64 Years
Sex
Female
01

Study summary

This is a prospective, triple-blinded and randomized controlled trial examining the effects of a home-based breathing training assisted with biofeedback on menopausal symptoms and autonomic functions among community menopausal women. We also examines whether the changes in autonomic functions would be mediators between slow breathing and menopausal symptoms. This study will include menopausal women, aged from 45 to 64, who experienced menopausal symptoms. Participants will be randomly assigned to either an intervention group (n = 80) or a waiting-list control group (n = 80). The intervention group will undergo the home-based breathing training 20 minutes twice daily and participants in the control condition will participate the same breathing training after a four-week waiting list period. The primary outcome measures are menopausal symptoms measured by symptom diaries of menopausal symptoms and the Greene Climacteric Scale (GCS). Secondary outcome measures are autonomic functions expressed by blood pressure (BP), heart rate (HR) and heart rate variability (HRV). Measurements will be taken at baseline, week 4, and week 8.

Read the detailed description

Ditto

02

Conditions studied

  • Menopause
  • Menopause Related Conditions
03

Who can participate

Ages eligible
45 Years to 64 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • aged from 45 to 64, reporting cessation of menstrual cycles with natural causes ≧ 12 consecutive months
  • the Greene Climacteric Scale (GCS) Chinese version scores ≧ 1

Exclusion criteria

Exclusion Criteria:

  • clinically diagnosed with history of cardiac arrhythmia, coronary heart disease, heart failure, kidney disease, hypertension, chronic low blood pressure, diabetic neuropathy, psychosis or mental deficiency
  • received hormone replacement therapy prescribed by gynecological physicians
  • took cardiac medications which may affect the autonomic functions, ex., β-blockers, etc.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    intervention group

    The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks

    Behavioral: home-based breathing training

  • Other
    waiting-list control group

    Participants in the control condition will conduct the same breathing training as the intervention group after a four-week waiting list period

    Behavioral: home-based breathing training

Interventions

  • Behavioralhome-based breathing training

    The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.

05

What researchers measure

Primary outcomes

  1. Menopausal symptoms

    Assessments using the Greene Climacteric Scale (GCS) for self-reported menopausal symptoms

    Time frame: Baseline

  2. Menopausal symptoms

    Assessments using the Greene Climacteric Scale (GCS) for self-reported menopausal symptoms

    Time frame: Posttest (4 weeks from baseline)

Secondary outcomes

  1. Autonomic functions (Blood pressure)

    Assessments using A\&D sphygmomanometer (Model 767Plus, A\&D Co., LTD., Japan) for systolic blood pressure and diastolic blood pressure

    Time frame: Baseline

  2. Autonomic functions (Blood pressure)

    Assessments using A\&D sphygmomanometer (Model 767Plus, A\&D Co., LTD., Japan) for systolic blood pressure and diastolic blood pressure

    Time frame: Posttest (4 weeks from baseline)

  3. Autonomic functions (heart rate)

    Assessments using EKG sensors to detect heartbeat signals, and then be analyzed by the BioGraph Infiniti software.

    Time frame: Baseline

  4. Autonomic functions (heart rate)

    Assessments using EKG sensors to detect heartbeat signals, and then be analyzed by the BioGraph Infiniti software.

    Time frame: Posttest (4 weeks from baseline)

  5. Autonomic functions (heart rate variability)

    A 3-lead EKG and Cardiopro Software were used to assess and analyze the heart rate variability in time domain, including SDNN (standard deviation of all NN intervals), rMSSD (the root mean square successive difference of normal-to-normal intervals) and pNN50 (NN50 count divided by the total number of all NN intervals).

    Time frame: Baseline

  6. Autonomic functions (heart rate variability)

    A 3-lead EKG and Cardiopro Software were used to assess and analyze the heart rate variability in time domain, including SDNN (standard deviation of all NN intervals), rMSSD (the root mean square successive difference of normal-to-normal intervals) and pNN50 (NN50 count divided by the total number of all NN intervals).

    Time frame: Posttest (4 weeks from baseline)

06

Study locations

1 site
  • Fu Jen Catholic University
    New Taipei City, Xinzhuang Dist 24205, Taiwan
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03082040
Lead sponsor
Ministry of Science and Technology, Taiwan
Responsible party
Yuh-Kae Shyu (Assistant Professor, Ministry of Science and Technology, Taiwan) — Principal investigator
First posted
Mar 17, 2017
Start date
Oct 26, 2016
Primary completion
Dec 20, 2017
Completion
Dec 20, 2017
Last update
Jun 5, 2020

Study contacts

Yuh-Kae Shyu, PhD
principal investigator · Fu Jen Catholic University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion